CRNX

Crinetics Pharmaceuticals, Inc. NASDAQ Listed Jul 18, 2018

Healthcare ·Biotechnology ·US · crinetics.com

$43.48

Mkt Cap $4.6B

52w Low $25.83 54.9% of range 52w High $57.99

50d MA $38.40 200d MA $40.82

P/E (TTM) -7.9x

EV/EBITDA -9.4x

P/B 3.7x

Debt/Equity 0.1x

ROE -46.9%

P/FCF -11.4x

RSI (14) —

ATR (14) —

Beta 0.31

50d MA $38.40

200d MA $40.82

Avg Volume 1.1M

About

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as we…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Feb 26, 2026	AMC	-1.37	-1.29	+5.8%	43.74	+3.2%	-6.0%	-7.0%	-8.3%	-9.7%	-11.1%	—
Nov 6, 2025	AMC	-1.27	-1.38	-8.7%	43.49	-7.9%	-8.0%	-4.7%	-1.3%	-1.5%	-4.7%	—
Aug 7, 2025	AMC	-1.13	-1.23	-8.8%	27.88	-0.5%	-3.7%	-1.8%	+2.2%	+7.9%	+6.5%	—
May 8, 2025	AMC	-0.99	-1.04	-5.1%	32.70	+1.8%	-6.2%	+1.9%	-5.4%	-4.3%	-4.6%	—
Feb 27, 2025	AMC	-0.92	-0.88	+4.3%	33.21	+2.2%	+7.7%	+2.8%	+2.6%	+2.2%	+2.7%	—
Nov 12, 2024	AMC	-0.91	-0.96	-5.4%	58.78	+2.1%	+0.2%	+1.5%	-6.9%	-8.6%	-6.1%	—
Aug 8, 2024	AMC	-0.86	-0.94	-9.3%	50.74	-4.7%	-6.1%	-2.3%	-0.8%	+1.4%	+3.5%	—
May 9, 2024	AMC	-0.84	-0.93	-10.7%	49.42	+0.0%	-2.9%	-3.0%	-0.1%	+2.2%	+5.0%	—
Feb 28, 2024	AMC	-0.89	-0.90	-1.1%	42.76	+5.4%	-4.3%	+7.6%	+1.8%	+0.4%	+1.8%	—
Nov 7, 2023	AMC	-0.89	-1.01	-13.5%	29.52	-1.5%	-3.6%	-9.6%	-8.8%	-4.2%	-2.9%	—
Aug 8, 2023	AMC	-0.85	-0.94	-10.6%	17.30	+1.0%	-3.6%	-2.9%	-4.5%	-2.7%	-3.4%	—
May 4, 2023	AMC	-0.82	-0.85	-3.7%	21.37	+3.3%	+4.6%	+3.1%	+10.4%	+9.2%	+3.5%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 28	Citizens	Maintains	Market Outperform → Market Outperform	—	$38.62	$39.41	+2.0%	-1.2%	-0.5%	+0.4%	+1.0%	—
Mar 2	Citizens	Maintains	Market Outperform → Market Outperform	—	$41.10	$40.46	-1.6%	-1.0%	-2.4%	-3.9%	-5.4%	-7.0%
Jan 12	Goldman Sachs	Upgrade	Neutral → Buy	—	$53.25	$54.10	+1.6%	+3.9%	+2.0%	+4.1%	+6.0%	+5.1%
Jan 8	Citizens	Maintains	Market Outperform → Market Outperform	—	$53.34	$53.30	-0.1%	-0.2%	-0.2%	+3.8%	+1.8%	+3.9%
Jan 6	Morgan Stanley	Maintains	Overweight → Overweight	—	$48.18	$47.40	-1.6%	-4.6%	+10.7%	+10.5%	+10.5%	+14.9%
Nov 7	Citizens	Maintains	Market Outperform → Market Outperform	—	$43.49	$40.06	-7.9%	-8.0%	-4.7%	-1.3%	-1.5%	-4.7%
Sep 30	Oppenheimer	Maintains	Outperform → Outperform	—	$43.51	$43.43	-0.2%	-4.3%	-4.4%	-4.6%	-6.1%	-4.2%
Sep 29	Leerink Partners	Maintains	Outperform → Outperform	—	$45.91	$45.91	+0.0%	-5.2%	-9.3%	-9.4%	-9.6%	-11.0%
Sep 29	Morgan Stanley	Maintains	Overweight → Overweight	—	$45.91	$45.91	+0.0%	-5.2%	-9.3%	-9.4%	-9.6%	-11.0%
Sep 26	Goldman Sachs	Maintains	Neutral → Neutral	—	$35.89	$41.07	+14.4%	+27.9%	+21.2%	+16.0%	+15.9%	+15.7%
Sep 26	Baird	Maintains	Outperform → Outperform	—	$35.89	$41.07	+14.4%	+27.9%	+21.2%	+16.0%	+15.9%	+15.7%
Sep 26	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$35.89	$41.07	+14.4%	+27.9%	+21.2%	+16.0%	+15.9%	+15.7%
Sep 24	JP Morgan	Maintains	Overweight → Overweight	—	$35.86	$35.34	-1.5%	-1.9%	+0.1%	+28.0%	+21.3%	+16.1%
Aug 11	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$26.85	$26.78	-0.3%	+2.0%	+6.1%	+12.1%	+10.6%	+14.4%
Jun 27	HC Wainwright & Co.	Maintains	Buy → Buy	—	$29.99	$30.12	+0.4%	-0.1%	-4.1%	-5.2%	-1.8%	-0.6%
Feb 28	Citizens Capital Markets	Maintains	Market Outperform → Market Outperform	—	$33.21	$33.94	+2.2%	+7.7%	+2.8%	+2.6%	+2.2%	+2.7%
Jan 22	Jefferies	Upgrade	Hold → Buy	—	$38.76	$40.00	+3.2%	-0.3%	+1.1%	+0.1%	-1.4%	-1.4%
Jan 13	HC Wainwright & Co.	Maintains	Buy → Buy	—	$40.59	$40.74	+0.4%	-4.0%	-12.2%	-9.5%	-10.1%	-8.0%
Dec 16	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$53.66	$53.21	-0.8%	+1.8%	+3.2%	-2.9%	-1.7%	-0.1%
Nov 14	Citigroup	Maintains	Buy → Buy	—	$58.92	$58.28	-1.1%	+1.3%	-7.1%	-8.9%	-6.4%	-4.8%
Nov 13	HC Wainwright & Co.	Maintains	Buy → Buy	—	$58.78	$60.00	+2.1%	+0.2%	+1.5%	-6.9%	-8.6%	-6.1%
Sep 27	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$50.58	$51.23	+1.3%	+0.3%	+1.0%	+2.6%	+6.8%	+4.3%
Sep 16	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$53.80	$53.90	+0.2%	+0.3%	-1.5%	-1.9%	+0.1%	-1.2%
Aug 9	HC Wainwright & Co.	Maintains	Buy → Buy	—	$50.74	$48.36	-4.7%	-6.1%	-2.3%	-0.8%	+1.4%	+3.5%
Aug 9	Oppenheimer	Maintains	Outperform → Outperform	—	$50.74	$48.36	-4.7%	-6.1%	-2.3%	-0.8%	+1.4%	+3.5%
Jul 9	JP Morgan	Maintains	Overweight → Overweight	—	$45.37	$45.79	+0.9%	+6.3%	+12.0%	+16.4%	+18.3%	+19.3%
Jul 2	Piper Sandler	Maintains	Overweight → Overweight	—	$46.07	$46.09	+0.0%	-1.2%	-4.1%	-4.9%	-1.5%	+4.7%
Jun 28	HC Wainwright & Co.	Maintains	Buy → Buy	—	$43.47	$43.67	+0.5%	+3.0%	+6.0%	+4.8%	+1.7%	+0.8%
Jun 4	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$46.28	$46.67	+0.8%	+2.3%	+2.1%	-1.0%	-3.4%	-2.7%
Jun 4	HC Wainwright & Co.	Maintains	Buy → Buy	—	$46.28	$46.67	+0.8%	+2.3%	+2.1%	-1.0%	-3.4%	-2.7%
Jun 4	Oppenheimer	Maintains	Outperform → Outperform	—	$46.28	$46.67	+0.8%	+2.3%	+2.1%	-1.0%	-3.4%	-2.7%
May 23	Morgan Stanley	Maintains	Overweight → Overweight	—	$50.54	$51.52	+1.9%	-3.8%	-6.1%	-7.3%	-9.4%	-10.2%
May 23	HC Wainwright & Co.	Maintains	Buy → Buy	—	$50.54	$51.52	+1.9%	-3.8%	-6.1%	-7.3%	-9.4%	-10.2%
May 23	Baird	Maintains	Outperform → Outperform	—	$50.54	$51.52	+1.9%	-3.8%	-6.1%	-7.3%	-9.4%	-10.2%
May 14	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$47.93	$48.71	+1.6%	+3.0%	+5.3%	+8.3%	+7.2%	+5.6%
May 10	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$49.42	$49.43	+0.0%	-2.9%	-3.0%	-0.1%	+2.2%	+5.0%
May 10	HC Wainwright & Co.	Maintains	Buy → Buy	—	$49.42	$49.43	+0.0%	-2.9%	-3.0%	-0.1%	+2.2%	+5.0%
May 7	Piper Sandler	Maintains	Overweight → Overweight	—	$46.50	$47.82	+2.8%	+2.5%	+9.4%	+6.3%	+3.2%	+3.1%
Mar 28	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$44.43	$44.52	+0.2%	+5.4%	+4.7%	+3.5%	+7.2%	+5.0%
Mar 20	JonesTrading	Maintains	Buy → Buy	—	$45.18	$44.23	-2.1%	+0.7%	-0.5%	-2.0%	-4.6%	-4.0%
Mar 20	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$45.18	$44.23	-2.1%	+0.7%	-0.5%	-2.0%	-4.6%	-4.0%
Mar 20	Oppenheimer	Maintains	Outperform → Outperform	—	$45.18	$44.23	-2.1%	+0.7%	-0.5%	-2.0%	-4.6%	-4.0%
Mar 20	HC Wainwright & Co.	Maintains	Buy → Buy	—	$45.18	$44.23	-2.1%	+0.7%	-0.5%	-2.0%	-4.6%	-4.0%
Mar 19	HC Wainwright& Co.	Maintains	Buy → Buy	—	$37.93	$41.07	+8.3%	+19.1%	+19.9%	+18.6%	+16.8%	+13.7%
Mar 19	HC Wainwright & Co.	Maintains	Buy → Buy	—	$37.93	$41.07	+8.3%	+19.1%	+19.9%	+18.6%	+16.8%	+13.7%
Mar 13	Oppenheimer	Maintains	Outperform → Outperform	—	$40.75	$41.08	+0.8%	-0.6%	-6.2%	-4.5%	-6.9%	+10.9%
Mar 13	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$40.75	$41.08	+0.8%	-0.6%	-6.2%	-4.5%	-6.9%	+10.9%
Mar 13	HC Wainwright & Co.	Maintains	Buy → Buy	—	$40.75	$41.08	+0.8%	-0.6%	-6.2%	-4.5%	-6.9%	+10.9%
Mar 8	HC Wainwright & Co.	Maintains	Buy → Buy	—	$42.50	$44.32	+4.3%	-0.5%	-2.2%	-4.1%	-4.7%	-10.1%
Mar 4	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$46.03	$47.58	+3.4%	-5.5%	-6.7%	-5.5%	-7.7%	-8.1%

Recent Filings

8-K

Unknown — 8-K Filing

A key executive's departure with limited post-employment option exercise rights suggests leadership transition risk, potentially pressuring CRNX stock if the departing officer held critical operational or strategic responsibilities.

Apr 10

8-K

Unknown — 8-K Filing

I cannot provide a meaningful analysis from this filing summary, as it contains only technical XBRL metadata rather than substantive business information about CRNX's operations, financial results, or strategic developments.

Mar 23

8-K · 4.01 !!! Very High

Crinetics Pharmaceuticals, Inc. -- 8-K 4.01: Auditor Change / Resignation

Crinetics Pharmaceuticals replaced its auditor from BDO to an undisclosed firm, which may signal accounting concerns or reflect routine auditor rotation and could affect investor confidence in financial reporting.

Mar 3

8-K

Crinetics Pharmaceuticals, Inc. -- 8-K Filing

Crinetics Pharmaceuticals reported full-year 2025 financial results, providing investors with updated operational performance and pipeline progress for its endocrine disease therapeutics portfolio.

Feb 26

Data updated apr 25, 2026 3:19am · Source: massive.com